Ipsen SA initiates a share buy-back program to cover its free employee share-allocation plan
REGULATED INFORMATION
Ipsen initiates a share buy-back program
to cover its free employee share-allocation plan
Paris (France), 1 June 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) has appointed an investment-services provider to purchase an aggregate number of Ipsen S.A. shares up to 350,000, or about 0.42% of the share capital, over a maximum period of six months. The shares purchased under this agreement will be allocated mainly to cover Ipsen’s free employee share-allocation plan.
This program is made pursuant to the authorization granted by the Company’s Combined Shareholders’ meeting, held on 31 May 2023.
Ipsen
Ipsen is a global, mid-sized biopharmaceutical company focused on transformative medicines in Oncology, Rare Disease and Neuroscience. With total sales of €3.0bn in FY 2022, Ipsen sells medicines in over 100 countries. Alongside its external-innovation strategy, the Company’s research and development efforts are focused on its innovative and differentiated technological platforms located in the heart of leading biotechnological and life-science hubs: Paris-Saclay, France; Oxford, U.K.; Cambridge, U.S.; Shanghai, China. Ipsen has around 5,000 colleagues worldwide and is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com.
Contacts
| Investors | |
| Craig Marks Vice President, Investor Relations +44 7584 349 193 | Nicolas Bogler Senior Manager, Investor Relations +33 (0) 6 52 19 98 92 |
| Media | |
| Amy Wolf Vice President and Head of Corporate Brand Strategy and Communications +41 79 576 07 23 | Ioana Piscociu Senior Manager, Global Media Relations +33 6 69 09 12 96 |
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
Combined Shareholders’ Meeting of Ipsen S.A. held on 31 May 2023
Description of the regulatory framework of the share repurchase program to be approved at the Combined Shareholders’ Meeting on 31 May 2023
Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio
Combined Shareholders’ Meeting of 24 May 2022
Combined Shareholders’ Meeting of 30 May 2018